Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 265

1.

Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors.

Necchi A, Ross JS, Spiess PE.

J Clin Oncol. 2019 Sep 10;37(26):2314-2316. doi: 10.1200/JCO.19.01672. Epub 2019 Jul 30. No abstract available.

PMID:
31361537
2.

Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection.

Chipollini J, Azizi M, Lo Vullo S, Mariani L, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg O, Heidenreich A, Raggi D, Catanzaro M, Ornellas P, Salvioni R, Cheriyan SK, Necchi A, Spiess PE.

BJU Int. 2019 Jul 29. doi: 10.1111/bju.14883. [Epub ahead of print]

PMID:
31356716
3.

Survival Following Salvage Surgery after Failed Radiotherapy for Penile Cancer: A SEER-Based Study.

Khalil MI, Wan F, Eltahawy E, Davis R, Spiess PE, Bissada NK, Kamel MH.

Curr Urol. 2019 May 10;12(3):142-146. doi: 10.1159/000489432.

4.

Patient presentation, differential diagnosis, and management of penile lesions.

Chipollini J, De la Rosa AH, Azizi M, Shayegan B, Zorn KC, Spiess PE.

Can Urol Assoc J. 2019 Feb;13(2 Suppl 1):S2-S8. doi: 10.5489/cuaj.5712. Review. No abstract available.

5.

Management of the Clinically Negative (cN0) Groin Penile Cancer Patient: A Review.

Kamel MH, Khalil MI, Davis R, Spiess PE.

Urology. 2019 Sep;131:5-13. doi: 10.1016/j.urology.2019.05.005. Epub 2019 May 24. Review.

PMID:
31129195
6.

Treating advanced penile cancer: where do we stand in 2019?

Aydin AM, Cheriyan S, Spiess PE.

Curr Opin Support Palliat Care. 2019 Sep;13(3):249-254. doi: 10.1097/SPC.0000000000000431.

PMID:
31082941
7.
8.

Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study.

Necchi A, Lo Vullo S, Mariani L, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M, Salvioni R, Chipollini J, Azizi M, Spiess PE.

Urol Oncol. 2019 Aug;37(8):531.e7-531.e15. doi: 10.1016/j.urolonc.2019.04.003. Epub 2019 May 1.

PMID:
31053524
9.

Updates in the molecular epidemiology and systemic approaches to penile cancer.

Adashek JJ, Necchi A, Spiess PE.

Urol Oncol. 2019 Jul;37(7):403-408. doi: 10.1016/j.urolonc.2019.04.012. Epub 2019 May 1. Review.

PMID:
31053523
10.

Important caveats of KEYNOTE-045: relevance of these findings in the current and future therapeutic paradigm.

Slongo J, Jain RK, Spiess PE.

Ann Transl Med. 2019 Mar;7(Suppl 1):S23. doi: 10.21037/atm.2019.01.81. No abstract available.

12.

Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.

Azizi M, Cheriyan SK, Peyton CC, Foerster B, Shariat SF, Spiess PE.

Curr Treat Options Oncol. 2019 Apr 1;20(5):40. doi: 10.1007/s11864-019-0637-2. Review.

PMID:
30937554
13.

Best videos and reviewer of the year selection 2018.

Spiess PE.

Int Braz J Urol. 2019 Jan-Feb;45(1):3-4. doi: 10.1590/S1677-5538.IBJU.2019.01.02. No abstract available.

14.

Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.

Li R, Spiess PE, Gilbert SM, Necchi A.

Eur Urol. 2019 Jul;76(1):4-6. doi: 10.1016/j.eururo.2019.02.027. Epub 2019 Mar 2.

PMID:
30833139
15.

Updates on the Management of Rare Genitourinary Malignancies: Where Do We Stand?

Spiess PE.

Eur Urol Focus. 2019 Feb 13. pii: S2405-4569(19)30023-9. doi: 10.1016/j.euf.2019.02.003. [Epub ahead of print] No abstract available.

PMID:
30772359
16.

Important surgical concepts and techniques in inguinal lymph node dissection.

Chipollini J, Garcia-Castaneda J, Harb-De la Rosa A, Cheriyan S, Azizi M, Spiess PE.

Curr Opin Urol. 2019 May;29(3):286-292. doi: 10.1097/MOU.0000000000000591.

PMID:
30730389
17.

The relationship between HPV and penile cancer: Filling a knowledge gap in the general population.

Slongo J, Giuliano AR, Johnstone PA, Spiess PE.

Can Urol Assoc J. 2019 Feb;13(2):38. doi: 10.5489/cuaj.5838. No abstract available.

18.

Editorial: penile cancer.

Albersen M, Spiess PE.

Curr Opin Urol. 2019 Mar;29(2):143-144. doi: 10.1097/MOU.0000000000000586. No abstract available.

PMID:
30601185
19.

New directions in penile cancer.

Johnstone PAS, Spiess PE, Giuliano AR.

Lancet Oncol. 2019 Jan;20(1):16-17. doi: 10.1016/S1470-2045(18)30695-8. Epub 2018 Dec 17. No abstract available.

PMID:
30573286
20.

Important Therapeutic Considerations in T1b Penile Cancer: Prognostic Significance and Adherence to Treatment Guidelines.

Zhu Y, Gu WJ, Xiao WJ, Wang BH, Azizi M, Spiess PE, Ye DW.

Ann Surg Oncol. 2019 Feb;26(2):685-691. doi: 10.1245/s10434-018-7066-5. Epub 2018 Dec 18.

PMID:
30565040
21.

ASO Author Reflections: T1b Penile Cancer: An Alarm to Improve Treatment.

Zhu Y, Spiess PE, Ye DW.

Ann Surg Oncol. 2019 Feb;26(2):692-693. doi: 10.1245/s10434-018-7081-6. Epub 2018 Dec 17. No abstract available.

PMID:
30556119
22.

Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what.

Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE.

World J Urol. 2018 Dec 7. doi: 10.1007/s00345-018-2591-1. [Epub ahead of print]

PMID:
30535583
23.

Epidural anesthesia and cancer outcomes in bladder cancer patients: is it the technique or the medication? A matched-cohort analysis from a tertiary referral center.

Chipollini J, Alford B, Boulware DC, Forget P, Gilbert SM, Lockhart JL, Pow-Sang JM, Sexton WJ, Spiess PE, Poch MA, Patel SY.

BMC Anesthesiol. 2018 Nov 3;18(1):157. doi: 10.1186/s12871-018-0622-5.

24.

Implications of Programmed Death Ligand-1 Positivity in Non-Clear Cell Renal Cell Carcinoma.

Chipollini J, Azizi M, Peyton CC, Tang DH, Dhillon J, Spiess PE.

J Kidney Cancer VHL. 2018 Oct 13;5(4):6-13. doi: 10.15586/jkcvhl.2018.107. eCollection 2018.

25.

Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study.

Cindolo L, Spiess PE, Bada M, Chipollini JJ, Nyirády P, Chiodini P, Varga J, Ditonno P, Battaglia M, De Nunzio C, Tema G, Veccia A, Antonelli A, Musi G, De Cobelli O, Conti A, Micali S, Álvarez-Maestro M, Olarte JQ, Diogenes E, Lima MVA, Tracey A, Guruli G, Autorino R, Sountoulides P, Schips L.

World J Urol. 2019 Aug;37(8):1649-1657. doi: 10.1007/s00345-018-2549-3. Epub 2018 Oct 30.

PMID:
30377813
26.

Primary Penile Cancer: The Role of Adjuvant Radiation Therapy in the Management of Extranodal Extension in Lymph Nodes.

Johnstone PAS, Boulware D, Djajadiningrat R, Ottenhof S, Necchi A, Catanzaro M, Ye D, Zhu Y, Nicolai N, Horenblas S, Spiess PE.

Eur Urol Focus. 2018 Oct 13. pii: S2405-4569(18)30300-6. doi: 10.1016/j.euf.2018.10.007. [Epub ahead of print]

PMID:
30327282
27.

Impact of PI3K-AKT-mTOR Signaling Pathway Up-regulation on Prognosis of Penile Squamous-Cell Carcinoma: Results From a Tissue Microarray Study and Review of the Literature.

Azizi M, Tang DH, Verduzco D, Peyton CC, Chipollini J, Yuan Z, Schaible BJ, Zhou JM, Johnstone PA, Giuliano A, Dhillon J, Spiess PE.

Clin Genitourin Cancer. 2019 Feb;17(1):e80-e91. doi: 10.1016/j.clgc.2018.09.012. Epub 2018 Sep 22.

PMID:
30318447
28.

Current controversies and developments on the role of lymphadenectomy for penile cancer.

Azizi M, Chipollini J, Peyton CC, Cheriyan SK, Spiess PE.

Urol Oncol. 2019 Mar;37(3):201-208. doi: 10.1016/j.urolonc.2018.08.017. Epub 2018 Oct 6. Review.

PMID:
30301700
29.

Primitive neuroectodermal tumor arising from an untreated congenital undescended testicle.

Azizi M, Peyton CC, Spiess PE.

Can J Urol. 2018 Oct;25(5):9530-9533.

PMID:
30281013
30.

Biomarkers and new therapeutic targets in renal cell carcinoma.

Di Pietro G, Luu HN, Spiess PE, Sexton W, Dickinson S, Parker A, Park JY.

Eur Rev Med Pharmacol Sci. 2018 Sep;22(18):5874-5891. doi: 10.26355/eurrev_201809_15916.

31.

Expansion of tumor infiltrating lymphocytes (TIL) from bladder cancer.

Poch M, Hall M, Joerger A, Kodumudi K, Beatty M, Innamarato PP, Bunch BL, Fishman MN, Zhang J, Sexton WJ, Pow-Sang JM, Gilbert SM, Spiess PE, Dhillon J, Kelley L, Mullinax J, Sarnaik AA, Pilon-Thomas S.

Oncoimmunology. 2018 Jul 23;7(9):e1476816. doi: 10.1080/2162402X.2018.1476816. eCollection 2018.

32.

The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy.

Peyton CC, Abel EJ, Chipollini J, Boulware DC, Azizi M, Karam JA, Margulis V, Master VA, Matin SF, Raman JD, Sexton WJ, Wood CG, Spiess PE.

Eur Urol Focus. 2018 Sep 8. pii: S2405-4569(18)30242-6. doi: 10.1016/j.euf.2018.08.023. [Epub ahead of print]

PMID:
30206003
33.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA.

J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.

PMID:
30181416
34.

Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer.

Peyton CC, Tang D, Reich RR, Azizi M, Chipollini J, Pow-Sang JM, Manley B, Spiess PE, Poch MA, Sexton WJ, Fishman M, Zhang J, Gilbert SM.

JAMA Oncol. 2018 Nov 1;4(11):1535-1542. doi: 10.1001/jamaoncol.2018.3542.

35.

Simulated management of urinary tract injury during robotic pelvic surgery utilizing the porcine model.

Hoffman MS, Spiess PE.

J Robot Surg. 2019 Apr;13(2):289-292. doi: 10.1007/s11701-018-0852-z. Epub 2018 Jul 16.

PMID:
30014233
36.

Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection.

Azizi M, Peyton CC, Boulware DC, Chipollini J, Juwono T, Pow-Sang JM, Spiess PE.

Eur Urol Focus. 2018 Jun 21. pii: S2405-4569(18)30156-1. doi: 10.1016/j.euf.2018.06.008. [Epub ahead of print]

PMID:
29937330
37.

Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy.

Vasdev N, Zargar H, Noël JP, Veeratterapillay R, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Morgan TM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Holzbeierlein JM, Thorpe A, Black PC.

World J Urol. 2019 Jan;37(1):165-172. doi: 10.1007/s00345-018-2361-0. Epub 2018 Jun 7.

PMID:
29882105
38.

Survival Outcomes Associated With Female Primary Urethral Carcinoma: Review of a Single Institutional Experience.

Peyton CC, Azizi M, Chipollini J, Ercole C, Fishman M, Gilbert SM, Juwono T, Lockhart J, Poch M, Pow-Sang JM, Spiess PE, Wiegand L, Sexton WJ.

Clin Genitourin Cancer. 2018 Oct;16(5):e1003-e1013. doi: 10.1016/j.clgc.2018.05.012. Epub 2018 May 18.

PMID:
29859736
39.

Improved Outcomes of Enhanced Recovery After Surgery (ERAS) Protocol for Radical Cystectomy with Addition of a Multidisciplinary Care Process in a US Comprehensive Cancer Care Center.

Patel SY, Garcia Getting RE, Alford B, Hussein K, Schaible BJ, Boulware D, Lee JK, Gilbert SM, Powsang JM, Sexton WJ, Spiess PE, Poch MA.

World J Surg. 2018 Sep;42(9):2701-2707. doi: 10.1007/s00268-018-4665-z.

PMID:
29750321
40.

Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention.

Chipollini J, Necchi A, Spiess PE.

Eur Urol. 2018 Aug;74(2):241-242. doi: 10.1016/j.eururo.2018.04.025. Epub 2018 May 3. No abstract available.

PMID:
29730019
41.

Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?

Li R, Spiess PE, Kamat AM.

Eur Urol. 2018 Oct;74(4):405-408. doi: 10.1016/j.eururo.2018.04.012. Epub 2018 Apr 22.

PMID:
29685644
42.

Multi-institutional Survival Analysis of Incidental Pathologic T3a Upstaging in Clinical T1 Renal Cell Carcinoma Following Partial Nephrectomy.

Russell CM, Lebastchi AH, Chipollini J, Niemann A, Mehra R, Morgan TM, Miller DC, Palapattu GS, Hafez KS, Sexton WJ, Spiess PE, Weizer AZ.

Urology. 2018 Jul;117:95-100. doi: 10.1016/j.urology.2018.04.002. Epub 2018 Apr 17.

PMID:
29678662
43.

The relationship between HPV status and chemoradiotherapy in the locoregional control of penile cancer.

Yuan Z, Naghavi AO, Tang D, Kim Y, Ahmed KA, Dhillon J, Giuliano AR, Spiess PE, Johnstone PA.

World J Urol. 2018 Sep;36(9):1431-1440. doi: 10.1007/s00345-018-2280-0. Epub 2018 Mar 27.

PMID:
29589134
44.

Surgical and Oncological Outcomes in Patients After Vascularised Flap Reconstruction for Locoregionally Advanced Penile Cancer.

Ottenhof SR, Leone A, Djajadiningrat RS, Azizi M, Zargar K, Kidd LC, Diorio G, Mosiello G, Graafland NM, Spiess PE, Horenblas S.

Eur Urol Focus. 2018 Feb 9. pii: S2405-4569(18)30026-9. doi: 10.1016/j.euf.2018.02.002. [Epub ahead of print]

PMID:
29433986
45.

Best videos of the year in 2017.

Spiess PE.

Int Braz J Urol. 2018 Jan-Feb;44(1):2-3. doi: 10.1590/S1677-5538.IBJU.2018.0002. No abstract available.

46.

The role of surgery in the management of metastatic kidney cancer: an evidence-based collaborative review.

Mir MC, Matin SF, Bex A, Spiess PE, Thompson RH, Grob B, van Poppel H.

Minerva Urol Nefrol. 2018 Apr;70(2):109-125. doi: 10.23736/S0393-2249.18.03055-2. Epub 2018 Jan 29.

47.

Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.

Zargar H, Shah JB, van Rhijn BW, Daneshmand S, Bivalacqua TJ, Spiess PE, Black PC, Kassouf W; Collaborators.

J Urol. 2018 Jun;199(6):1452-1458. doi: 10.1016/j.juro.2017.12.062. Epub 2018 Jan 9.

PMID:
29329894
48.

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer.

Kumar NB, Patel R, Pow-Sang J, Spiess PE, Salup R, Williams CR, Schell MJ.

Oncotarget. 2017 Jun 29;8(58):99093-99103. doi: 10.18632/oncotarget.18858. eCollection 2017 Nov 17.

49.

Penile sparing surgical approaches for primary penile tumors: preserving function and appearance.

Baumgarten AS, Fisher JS, Lawindy SM, Pavlinec JG, Carrion RE, Spiess PE.

Transl Androl Urol. 2017 Oct;6(5):809-819. doi: 10.21037/tau.2017.04.01. Review.

50.

Relationship between human papillomavirus and penile cancer-implications for prevention and treatment.

Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P.

Transl Androl Urol. 2017 Oct;6(5):791-802. doi: 10.21037/tau.2017.06.27. Review.

Supplemental Content

Loading ...
Support Center